Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice
Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study...
Gespeichert in:
Veröffentlicht in: | FASEB Journal 2011-09, Vol.25 (9), p.3208-3218 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3218 |
---|---|
container_issue | 9 |
container_start_page | 3208 |
container_title | FASEB Journal |
container_volume | 25 |
creator | Rat, Dorothea Schmitt, Ulrich Tippmann, Frank Dewachter, Ilse Theunis, Clara Wieczerzak, Ewa Postina, Rolf Van Leuven, Fred Fahrenholz, Falk Kojro, Elzbieta |
description | Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org |
format | Article |
fullrecord | <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_354447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_354447</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_3544473</originalsourceid><addsrcrecordid>eNqNjMFOwzAQRH0AiVL4B98KQpGcJk3TY1SBOKEeuEcrZ0mXOrZlb1rM5_ClBInee5rRaN67EjNVb5ZZVRX1jbiN8VMplau8momfNxyD8-iZOpSeeCSGkCR0aJMBRqmTNhAxA810BCbbS-9MOiMPu2bb7B5lNO4UZedOVjbme480YFhMA0X8ow0dJj3w3hnXJ0lWwpCMo076gHoM0YWpOUayGQewsUdLWg6k8U5cf4CJeP-fc7F4eX7fvmaH0eB4RNt20YPGNl8W5apa15u2WJVluS7m4umyZ8tfXFzu_QVOxGzj</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</title><source>Lirias (KU Leuven Association)</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Rat, Dorothea ; Schmitt, Ulrich ; Tippmann, Frank ; Dewachter, Ilse ; Theunis, Clara ; Wieczerzak, Ewa ; Postina, Rolf ; Van Leuven, Fred ; Fahrenholz, Falk ; Kojro, Elzbieta</creator><creatorcontrib>Rat, Dorothea ; Schmitt, Ulrich ; Tippmann, Frank ; Dewachter, Ilse ; Theunis, Clara ; Wieczerzak, Ewa ; Postina, Rolf ; Van Leuven, Fred ; Fahrenholz, Falk ; Kojro, Elzbieta</creatorcontrib><description>Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org</description><identifier>ISSN: 0892-6638</identifier><language>eng</language><publisher>9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA: The Federation of American Societies for Experimental Biology</publisher><ispartof>FASEB Journal, 2011-09, Vol.25 (9), p.3208-3218</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,776,780,27837</link.rule.ids></links><search><creatorcontrib>Rat, Dorothea</creatorcontrib><creatorcontrib>Schmitt, Ulrich</creatorcontrib><creatorcontrib>Tippmann, Frank</creatorcontrib><creatorcontrib>Dewachter, Ilse</creatorcontrib><creatorcontrib>Theunis, Clara</creatorcontrib><creatorcontrib>Wieczerzak, Ewa</creatorcontrib><creatorcontrib>Postina, Rolf</creatorcontrib><creatorcontrib>Van Leuven, Fred</creatorcontrib><creatorcontrib>Fahrenholz, Falk</creatorcontrib><creatorcontrib>Kojro, Elzbieta</creatorcontrib><title>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</title><title>FASEB Journal</title><description>Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org</description><issn>0892-6638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqNjMFOwzAQRH0AiVL4B98KQpGcJk3TY1SBOKEeuEcrZ0mXOrZlb1rM5_ClBInee5rRaN67EjNVb5ZZVRX1jbiN8VMplau8momfNxyD8-iZOpSeeCSGkCR0aJMBRqmTNhAxA810BCbbS-9MOiMPu2bb7B5lNO4UZedOVjbme480YFhMA0X8ow0dJj3w3hnXJ0lWwpCMo076gHoM0YWpOUayGQewsUdLWg6k8U5cf4CJeP-fc7F4eX7fvmaH0eB4RNt20YPGNl8W5apa15u2WJVluS7m4umyZ8tfXFzu_QVOxGzj</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Rat, Dorothea</creator><creator>Schmitt, Ulrich</creator><creator>Tippmann, Frank</creator><creator>Dewachter, Ilse</creator><creator>Theunis, Clara</creator><creator>Wieczerzak, Ewa</creator><creator>Postina, Rolf</creator><creator>Van Leuven, Fred</creator><creator>Fahrenholz, Falk</creator><creator>Kojro, Elzbieta</creator><general>The Federation of American Societies for Experimental Biology</general><scope>FZOIL</scope></search><sort><creationdate>201109</creationdate><title>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</title><author>Rat, Dorothea ; Schmitt, Ulrich ; Tippmann, Frank ; Dewachter, Ilse ; Theunis, Clara ; Wieczerzak, Ewa ; Postina, Rolf ; Van Leuven, Fred ; Fahrenholz, Falk ; Kojro, Elzbieta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_3544473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rat, Dorothea</creatorcontrib><creatorcontrib>Schmitt, Ulrich</creatorcontrib><creatorcontrib>Tippmann, Frank</creatorcontrib><creatorcontrib>Dewachter, Ilse</creatorcontrib><creatorcontrib>Theunis, Clara</creatorcontrib><creatorcontrib>Wieczerzak, Ewa</creatorcontrib><creatorcontrib>Postina, Rolf</creatorcontrib><creatorcontrib>Van Leuven, Fred</creatorcontrib><creatorcontrib>Fahrenholz, Falk</creatorcontrib><creatorcontrib>Kojro, Elzbieta</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>FASEB Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rat, Dorothea</au><au>Schmitt, Ulrich</au><au>Tippmann, Frank</au><au>Dewachter, Ilse</au><au>Theunis, Clara</au><au>Wieczerzak, Ewa</au><au>Postina, Rolf</au><au>Van Leuven, Fred</au><au>Fahrenholz, Falk</au><au>Kojro, Elzbieta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice</atitle><jtitle>FASEB Journal</jtitle><date>2011-09</date><risdate>2011</risdate><volume>25</volume><issue>9</issue><spage>3208</spage><epage>3218</epage><pages>3208-3218</pages><issn>0892-6638</issn><abstract>Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent alpha-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid beta-peptide (A beta) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the A beta-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[ V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD.-Rat, D., Schmitt, U., Tippmann, F., Dewachter, I., Theunis, C., Wieczerzak, E, Postina, R., van Leuven, F., Fahrenholz, F., Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011). www.fasebj.org</abstract><cop>9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA</cop><pub>The Federation of American Societies for Experimental Biology</pub><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0892-6638 |
ispartof | FASEB Journal, 2011-09, Vol.25 (9), p.3208-3218 |
issn | 0892-6638 |
language | eng |
recordid | cdi_kuleuven_dspace_123456789_354447 |
source | Lirias (KU Leuven Association); Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
title | Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A23%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuropeptide%20pituitary%20adenylate%20cyclase-activating%20polypeptide%20(PACAP)%20slows%20down%20Alzheimer's%20disease-like%20pathology%20in%20amyloid%20precursor%20protein-transgenic%20mice&rft.jtitle=FASEB%20Journal&rft.au=Rat,%20Dorothea&rft.date=2011-09&rft.volume=25&rft.issue=9&rft.spage=3208&rft.epage=3218&rft.pages=3208-3218&rft.issn=0892-6638&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_354447%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |